| Literature DB >> 34987680 |
Tao Lin1, Qianhui Li1, Defu Jin1, Wanbo Liu1, Chaogui Tang1, Xiaoyun Zhang1.
Abstract
Staphylococcus aureus is the major pathogen causing nosocomial human infections and produces a variety of virulence factors that contribute to its ability to colonize and cause diseases. This study was conducted to investigate the virulence genes in S. aureus isolated from sterile body fluid samples and their correlation with clinical symptoms and outcomes. The VITEK 2® Compact system was used to perform biochemical identification and antimicrobial susceptibility tests on 33 S. aureus isolates. Virulence genes were amplified using multiplex PCR. The virulence gene patterns were analyzed by systematic cluster analysis. The frequency of methicillin-resistant S. aureus was 45.45%, and 17 virulence genes were identified. Genes encoding hemolysins showed high frequencies. The frequencies of hla, hlb, hld, and hlgB were 93.94% and that of the luk-F/S-PV was 21.21%. Except for the frequency of splB (51.52%), the remaining genes encoding invasive proteases showed frequencies greater than 81.82%. Among the patients, 100.00% had undergone invasive medical procedures and 24.00% had been treated with more than three types of antibiotic drugs. Invasive medical procedures are the main causes of infection. Resistance to antibiotic drugs and the status of carrying virulence genes were highly related to clinical symptoms and outcomes.Entities:
Year: 2021 PMID: 34987680 PMCID: PMC8720599 DOI: 10.1155/2021/5354747
Source DB: PubMed Journal: Can J Infect Dis Med Microbiol ISSN: 1712-9532 Impact factor: 2.471
Virulence factors, genes, primer sequences, and product length.
| Virulence factors | Genes | Primer name | Sequence (5′–3′) | Product length (bp) |
|---|---|---|---|---|
| Hemolysin |
|
| ATGAAAACACGTATAGTCAGCTCAGTAACAAC | 960 |
|
| TTAATTTGTCATTTCTTCTTTTTCCCAATCGA | |||
|
|
| AAATTAGAGCTGAACAAATGAAAGAAATCAG | 825 | |
|
| TTTCGCAATTGAATTTGATTGAGGGTCCC | |||
|
|
| ATGGCACAAGATATCATTTCAACAATCAGTG | 81 | |
|
| TTATTTTTTAGTGAATTTGTTCACTGTGTCG | |||
|
|
| ATGATTAAAAATAAAATATTAACAGCAACTTTAGCAGTT | 860 | |
|
| TTACTTAGGTGTGATGCTTTTAATTTTTACTTCATGTG | |||
|
|
| ATGAAAATGAATAAATTAGTCAAATCATCCGTTGC | 792 | |
|
| TTACTGTAATTTTAGATTTTTTAGCGCCATCTTG | |||
|
|
| GCTTAAAAATAAAATATTAACTACAACTTTATCTGTGAGC | 720 | |
|
| TCAATTCTGTCCTTTCACCTTGATTTCATGAG | |||
| Leukocidin |
|
| TTGTCAGTAGGACTGATTGCACCTTTAGC | 906 |
|
| TTAATTATGTCCTTTCACTTTAATTTCGTGTGTT | |||
|
|
| GTTTAAGAGAAAATTATTAGTTACAACTTTGTCGC | 864 | |
|
| GTTGTGCCCCTTTACTTTAATTTCGTG | |||
|
|
| ATGAAAAAAATAGTCAAATCATCAGTTGTTACATCA | 978 | |
|
| AGCTCATAGGATTTTTTTCCTTAGATTGAG | |||
|
|
| GGTCAAAAAAAGACTATTAGCTGCAACATTG | 939 | |
|
| TCAATTATGTCCTTTCACTTTAATTTCATGAGTTTTCC | |||
| Invasive proteases |
|
| GAACAAAAACGTAGTCATCAAGAGTTTAGCAGC | 723 |
|
| CTATGTTTTCTGCAATGAATTTTTTAATTTCTGGTGT | |||
|
|
| ATGAAAGGTAAATTTTTAAAAGTTAGTTCTTTATTCGT | 783 | |
|
| ATCTTCAATATTTTGTTTTAAGAAGTTGCGTACA | |||
|
|
| GTAAATCTAGAGTATTCAATATTATCAGCATCATAATGG | 792 | |
|
| AACCTATCATTGAACCATACCAGTTATAATCA | |||
|
|
| GTATCAACTACAATTTATAAATTTAGTTTACGACACAACC | 330 | |
|
| CTAAGCGCTCATAAACGATTGGGCGC | |||
| Hyaluronidase |
|
| ATGACATATAGAATGAAGAAATGGCAAAAATTATCCACC | 936 |
|
| TAATTCAAAGCGCACGCCGGATTCATTAGA | |||
| Staphylokinase |
|
| ATGCTCAAAAGAGGTTTATTATTTTTAACTGTTTT | 492 |
|
| ATTTCTTTTCTATAACAACCTTTGTAATTAAGTTG | |||
| Lipase |
|
| GTAGATTATGGTGCAGCACATGCAGCAAAATATGG | 921 |
|
| AGCTTTTCAGTTTTCACTAAATCGTCTGCT | |||
| Nuclease |
|
| AAGAGGTTTTTCTTTTTCGCTACTAGTTGC | 537 |
|
| CTCCAAATATTTAATTTCTGTTGTTTAGCTTT |
Antimicrobial resistance rate of the 33 Staphylococcus aureus strains.
| Antibiotics | Resistance rate ( | Intermediary rate ( | Sensitivity rate ( |
|---|---|---|---|
| Penicillin G | 33 (100.00) | 0 (0.00) | 0 (0.00) |
| Oxacillin | 15 (45.45) | 0 (0.00) | 18 (54.55) |
| Amoxicillin/clavulanic acid | 22 (66.67) | 0 (0.00) | 11 (33.33) |
| Gentamicin | 13 (39.39) | 0 (0.00) | 10 (30.30) |
| Ciprofloxacin | 24 (72.73) | 0 (0.00) | 9 (27.27) |
| Compound sulfamethoxazole | 21 (63.64) | 0 (0.00) | 12 (36.36) |
| Clindamycin | 15 (45.45) | 0 (0.00) | 18 (54.55) |
| Erythrocin | 28 (84.85) | 0 (0.00) | 5 (15.15) |
| Linezolid | 0 (0.00) | 0 (0.00) | 33 (100.00) |
| Teicoplanin | 0 (0.00) | 0 (0.00) | 33 (100.00) |
| Vancomycin | 0 (0.00) | 0 (0.00) | 33 (100.00) |
| Tigecycline | 0 (0.00) | 0 (0.00) | 33 (100.00) |
| Chloramphenicol | 2 (6.06) | 0 (0.00) | 31 (93.94) |
Distribution of virulence genes among MSSA and MRSA strains (%).
| Virulence genes | Frequency | |||
|---|---|---|---|---|
| Total number of strains ( | Number of MSSA strains ( | Number of MRSA strains ( |
| |
|
| 32 (96.97) | 17 (94.44) | 15 (100.00) | 0.27 |
|
| 32 (96.97) | 17 (94.44) | 15 (100.00) | 0.27 |
|
| 31 (93.94) | 17 (94.44) | 14 (93.33) | 0.89 |
|
| 29 (87.88) | 15 (83.33) | 14 (93.33) | 0.37 |
|
| 32 (96.97) | 17 (94.44) | 15 (100.00) | 0.27 |
|
| 29 (87.88) | 15 (83.33) | 1 (6.67) | ≤0.01 |
|
| 7 (21.21) | 1 (5.56) | 6 (40.00) | 0.01 |
|
| 17 (51.52) | 8 (44.44) | 9 (60.00) | 0.37 |
|
| 7 (21.21) | 5 (27.28) | 2 (13.33) | 0.30 |
|
| 30 (90.91) | 16 (88.89) | 14 (93.33) | 0.66 |
|
| 29 (87.88) | 3 (16.67) | 14 (93.33) | ≤0.01 |
|
| 27 (81.82) | 16 (88.89) | 12 (80.00) | 0.48 |
|
| 17 (51.52) | 8 (44.44) | 9 (60.00) | 0.37 |
|
| 10 (30.30) | 6 (33.33) | 4 (26.67) | 0.68 |
|
| 23 (69.70) | 13 (72.22) | 11 (73.33) | 0.94 |
|
| 28 (84.85) | 17 (94.44) | 15 (100.00) | 0.27 |
|
| 32 (96.97) | 13 (72.22) | 14 (93.33) | 0.10 |
Virulence gene patterns of 33 S. aureus strains.
| Serial number | Virulence gene patterns | Strain number | Number of genes ( | Total number of strains |
|---|---|---|---|---|
| 1 |
| 10 | 6 (0.35) | 1 |
| 2 |
| 15 | 5 (0.29) | 1 |
| 3 |
| 23 | 9 (0.53) | 1 |
| 4 |
| 30 | 5 (0.29) | 1 |
| 5 |
| 1, 2, 3, 4, 5, 6 | 15 (0.88) | 6 |
| 6 |
| 7 | 14 (0.82) | 1 |
| 7 |
| 8, 9 | 12 (0.71) | 2 |
| 8 |
| 11 | 11 (0.65) | 1 |
| 9 |
| 12 | 12 (0.71) | 1 |
| 10 |
| 13, 26, 27 | 12 (0.71) | 3 |
| 11 |
| 14 | 11 (0.65) | 1 |
| 12 |
| 16 | 13 (0.76) | 1 |
| 13 |
| 17 | 14 (0.82) | 1 |
| 14 |
| 18 | 12 (0.71) | 1 |
| 15 |
| 19, 20, 29 | 16 (0.94) | 3 |
| 16 |
| 21 | 11 (0.65) | 1 |
| 17 |
| 22, 31, 33 | 10 (0.59) | 3 |
| 18 |
| 24 | 14 (0.82) | 1 |
| 19 |
| 25 | 11 (0.65) | 1 |
| 20 |
| 28 | 14 (0.82) | 1 |
| 21 |
| 32 | 14 (0.82) | 1 |
Figure 1System cluster analysis of 33 Staphylococcus aureus virulence genes.
Clinical data of 33 patients with S. aureus infection.
| Clinical information | Number of patients ( | |
|---|---|---|
| Basic disease (7) | Diabetes | 6 (18.18) |
| Hypertension | 7 (21.21) | |
| Cardiovascular disease | 1 (3.03) | |
| Uremia | 1 (3.03) | |
| Trauma | 5 (15.15) | |
| Respiratory infection | 5 (15.15) | |
| Urinary tract infection | 1 (3.03) | |
|
| ||
| Sign (2) | Fever | 23 (69.70) |
| Chest film/CT with positive sign | 8 (24.24) | |
|
| ||
| Invasive medical procedures (4) | Percutaneous venous access | 8 (24.24) |
| Drainage tube | 12 (36.36) | |
| Indwelling catheter | 3 (9.09) | |
| Mechanical ventilation | 2 (6.06) | |
| Concomitant infection (1) | Gram-negative bacilli infection | 3 (9.09) |
|
| ||
| Outcome (5) | Cure | 4 (12.12) |
| Improved | 15 (45.45) | |
| Automatic discharge | 5 (15.15) | |
| Death | 2 (6.06) | |
| Other | 2 (6.06) | |
|
| ||
| Treated with more than three antibiotics | 8 (24.24) | |